This retrospective cohort analysis showed that NaturalVue Multifocal 1 Day contact lens wear appears to result in a mean refractive myopia progression of less than 0.25D per year, based on available data. Some limited axial length data was also presented.
This study investigated the accuracy of using pre-treatment axial elongation and changes in refractive sphere in predicting myopia control success in orthokeratology. Axial length was the more accurate method for categorisation of slow, moderate or rapid progression, and fast progressors benefited the most from ortho-k wear.
This paper identified time spent outdoors as the key factor in predicting better myopia control outcomes in children wearing with MiSight 1 day contact lenses. Other factors which weren’t predictive included age, refraction, binocular vision findings, pupil size and time spent at near.
This cross-over study investigated children wearing highly aspherical lenslet (HAL) spectacle lenses versus single vision spectacles over three six-month periods. The HAL lenses showed consistent myopia control efficacy and no rebound effect when discontinued over one of the six-month periods.
The age of onset of myopia influences the annual progression rate and is also race dependent. Delaying the onset of myopia can save approximately 0.75D a year on the final prescription reached, similar to the saving offered by myopia control methods.
Atropine 0.01% combined with orthokeratology slows axial elongation to less than 0.1mm/year over two years in Chinese children aged 6-11 years. This is the equal-longest study on this topic and first to measure potential mechanisms of pupil size and choroidal thickness. The largest effect of the combination occurred in the first 6 months.
In young adult myopes, Biofinity centre-distance +2.50 Add and NaturalVue multifocal contact lenses both showed reduced visual acuity in lower lighting and low contrast conditions, and especially with a glare source, compared to single vision. Reading rate under normal lighting was also reduced by 4-8%. The multifocal designs performed similarly, although Biofinity required more over-refraction for best distance acuity.
The IMI 2021 Yearly Digest summarized recent updates and progress in research of myopia, taking in all publications since the IMI Volume One reports published in early 2019. Each of the Volume One reports included an update – definitions, interventions, genetics, experimental models, clinical trial guidance, ethical considerations and clinical management. While further research is needed, the strengthening evidence base indicates eye care practitioners should embrace proactive myopia management.
In myopic children, interventions to slow progression are warranted to prevent the development of high myopia and subsequent pathology and also to reduce the economic burden caused by uncorrected and pathologic myopia. This IMI Report describes the latest advice on preventing the development and progression of myopia – read the summary here.
This meta-analysis investigated the effectiveness of orthokeratology in controlling the progression of anisomyopia (unilateral myopia or bilateral anisomyopia) in Chinese children. Total anisomyopia decreased at 2-year follow up, indicating orthokeratology may be a safe clinical method to slow myopia progression coupled with reducing interocular axial length difference.
